BioCentury | Mar 10, 2014
Company News

Olympus Corp. musculoskeletal news

...reasons. Olympus Biotech will discontinue its osteoinductive and osteoconductive bone graft materials OP-1 PUTTY and OPI-1...
BioCentury | Jan 27, 2014
Finance

Going big

...have included cancer play OPi S.A. and endoscopic tool manufacturer Mauna Kea Technologies S.A. (Euronext:MKEA). OPi...
BioCentury | May 5, 2008
Company News

Alize Pharma, EUSA, International Drug Development Institute deal

...Financial terms were not disclosed. EUSA acquired both programs as part of its acquisition of OPi...
BioCentury | Oct 22, 2007
Clinical News

Xenazine tetrabenazine regulatory update

...& Co. KG (Marburg, Germany) holds marketing rights to Nitoman in Germany and Austria, and OPi...
BioCentury | Sep 24, 2007
Company News

Alize Pharma board of directors update

...Alize Pharma S.A.S. , Lyon, France Business: Endocrine Appointed: Gilles Alberici, former president of OPi S.A. WIR...
BioCentury | May 14, 2007
Finance

Ebb & Flow

...the $175 million that went to specialty pharma EUSA for the acquisition of oncology company OPi...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...EUSA : a $175 million B round to fund its acquisition of orphan drug specialist OPi...
BioCentury | Mar 19, 2007
Company News

Cambridge Laboratories, Temmler sales and marketing update

...South Africa, New Zealand and Australia. Temmler has marketing rights in Germany and Austria, while OPi...
BioCentury | Mar 5, 2007
Company News

EUSA, Opi deal

...acquired OPi for more than E100 million ($131.7 million). The exact sum was not disclosed. OPi...
...leukemia (ALL). The company posted 2006 sales of $23 million. Further terms were not disclosed. OPi...
...and CEO Gilles Alberici joined EUSA's board. EUSA Pharma Inc. , King of Prussia, Penn. OPi...
BioCentury | Mar 5, 2007
Finance

Ebb & Flow

...came from specialty pharma EUSA , which raised $175 million to acquire French oncology-focused company OPi...
Items per page:
1 - 10 of 18
BioCentury | Mar 10, 2014
Company News

Olympus Corp. musculoskeletal news

...reasons. Olympus Biotech will discontinue its osteoinductive and osteoconductive bone graft materials OP-1 PUTTY and OPI-1...
BioCentury | Jan 27, 2014
Finance

Going big

...have included cancer play OPi S.A. and endoscopic tool manufacturer Mauna Kea Technologies S.A. (Euronext:MKEA). OPi...
BioCentury | May 5, 2008
Company News

Alize Pharma, EUSA, International Drug Development Institute deal

...Financial terms were not disclosed. EUSA acquired both programs as part of its acquisition of OPi...
BioCentury | Oct 22, 2007
Clinical News

Xenazine tetrabenazine regulatory update

...& Co. KG (Marburg, Germany) holds marketing rights to Nitoman in Germany and Austria, and OPi...
BioCentury | Sep 24, 2007
Company News

Alize Pharma board of directors update

...Alize Pharma S.A.S. , Lyon, France Business: Endocrine Appointed: Gilles Alberici, former president of OPi S.A. WIR...
BioCentury | May 14, 2007
Finance

Ebb & Flow

...the $175 million that went to specialty pharma EUSA for the acquisition of oncology company OPi...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...EUSA : a $175 million B round to fund its acquisition of orphan drug specialist OPi...
BioCentury | Mar 19, 2007
Company News

Cambridge Laboratories, Temmler sales and marketing update

...South Africa, New Zealand and Australia. Temmler has marketing rights in Germany and Austria, while OPi...
BioCentury | Mar 5, 2007
Company News

EUSA, Opi deal

...acquired OPi for more than E100 million ($131.7 million). The exact sum was not disclosed. OPi...
...leukemia (ALL). The company posted 2006 sales of $23 million. Further terms were not disclosed. OPi...
...and CEO Gilles Alberici joined EUSA's board. EUSA Pharma Inc. , King of Prussia, Penn. OPi...
BioCentury | Mar 5, 2007
Finance

Ebb & Flow

...came from specialty pharma EUSA , which raised $175 million to acquire French oncology-focused company OPi...
Items per page:
1 - 10 of 18